Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Defence Therapeutics Inc (DTC.CN)

Defence Therapeutics Inc (DTC.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 38,308
  • Shares Outstanding, K 54,725
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,522 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6300 +11.11%
on 12/19/25
0.9300 -24.73%
on 12/03/25
-0.1600 (-18.60%)
since 11/19/25
3-Month
0.6300 +11.11%
on 12/19/25
0.9300 -24.73%
on 12/03/25
-0.1000 (-12.50%)
since 09/19/25
52-Week
0.5200 +34.62%
on 12/20/24
1.6600 -57.83%
on 02/19/25
+0.1800 (+34.62%)
since 12/19/24

Most Recent Stories

More News
Defence Therapeutics Announces AGM Results and Provides Corporate Updates

Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular...

DTCFF : 0.4882 (-6.56%)
DTC.CN : 0.7000 (+1.45%)
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs

Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular...

DTCFF : 0.4882 (-6.56%)
DTC.CN : 0.7000 (+1.45%)
Defence Therapeutics Announces Convertible Debenture Conversion

Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation...

DTCFF : 0.4882 (-6.56%)
DTC.CN : 0.7000 (+1.45%)
Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology

Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation...

DTCFF : 0.4882 (-6.56%)
DTC.CN : 0.7000 (+1.45%)
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs

Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation...

DTCFF : 0.4882 (-6.56%)
DTC.CN : 0.7000 (+1.45%)
Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models

Montreal, Quebec--(Newsfile Corp. - November 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug...

DTCFF : 0.4882 (-6.56%)
DTC.CN : 0.7000 (+1.45%)
Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025

Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug...

DTCFF : 0.4882 (-6.56%)
DTC.CN : 0.7000 (+1.45%)
Upcoming Meeting Dates - October 13, 2025

Toronto, Ontario--(Newsfile Corp. - October 13, 2025) -  The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies...

NOBL.VN : 0.150 (+7.14%)
SKP.VN : 0.140 (+3.70%)
HTRC.CN : 0.1750 (-5.41%)
CAD.VN : 2.210 (+6.76%)
OTEX.TO : 46.06 (-0.17%)
DGX.VN : 4.070 (+20.77%)
LCX.VN : 0.560 (unch)
ROK.VN : 0.225 (unch)
HCC.VN : 0.010 (unch)
JJ.VN : 0.100 (unch)
ACS.VN : 0.095 (-42.42%)
KLM.VN : 0.005 (unch)
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025

Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug...

DTCFF : 0.4882 (-6.56%)
DTC.CN : 0.7000 (+1.45%)
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations

Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug...

DTCFF : 0.4882 (-6.56%)
DTC.CN : 0.7000 (+1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research...

See More

Key Turning Points

3rd Resistance Point 0.7933
2nd Resistance Point 0.7467
1st Resistance Point 0.7233
Last Price 0.7000
1st Support Level 0.6533
2nd Support Level 0.6067
3rd Support Level 0.5833

See More

52-Week High 1.6600
Fibonacci 61.8% 1.2245
Fibonacci 50% 1.0900
Fibonacci 38.2% 0.9555
Last Price 0.7000
52-Week Low 0.5200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar